Aerosol antibiotics plus pembrolizumab for advanced lung cancer
Treatments studied
Part of Cancer, Infections, Lungs & breathing clinical trials.
This trial studies whether inhaled (aerosol) antibiotics combined with pembrolizumab can help people with advanced non-small cell lung cancer that has grown despite standard first treatment. It aims to improve cancer control by testing this new combination in Phase 1 safety and early effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have non-small cell lung cancer confirmed by a pathology test (from a lab report).
- Your cancer has measurable spots that cannot be removed with surgery.
- Your tumor test shows PD-L1 is at least 1%, using an FDA-approved test method.
- Your cancer has progressed after at least one FDA-approved frontline (first) treatment.
- You are 18 or older, and you can do most daily activities (ECOG 0–2).
- Your blood counts and organ function meet required lab ranges (and kidney function is sufficient).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial studies whether pembrolizumab combined with standard chemo can treat locally advanced, unresectable stage III lung cancer without giving radiation first. It is intended for people whose tumor has high PD-L1 (a marker linked to how well immunotherapy may work).
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
Hear when a new Advanced Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.